Label: OBREDON- hydrocodone bitartrate and guaifenesin solution
- NDC Code(s): 58716-433-04, 58716-433-16
- Packager: Sovereign Pharmaceuticals, LLC
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: CII
- Marketing Status: New Drug Application
Updated November 17, 2020
If you are a consumer or patient please visit this version.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use OBREDON ® safely and effectively. See full prescribing information for OBREDON.
OBREDON (hydrocodone bitartrate and guaifenesin) oral solution CII
Initial U.S. Approval: 2014
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME
See full prescribing information for complete boxed warning.
- OBREDON exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor closely for these behaviors and conditions. ( 5.1)
- Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or when used in patients at higher risk. ( 5.2)
- Accidental ingestion of OBREDON, especially by children, can result in a fatal overdose of hydrocodone. ( 5.2)
- Ensure accuracy when prescribing, dispensing, and administering OBREDON. Dosing errors can result in accidental overdose and death. ( 2.1, 5.2)
- Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. Avoid the use of OBREDON in patients taking CYP3A4 inhibitors or inducers. ( 5.7, 7.2, 7.3)
- Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of OBREDON in patients taking benzodiazepines, other CNS depressants, or alcohol. ( 5.8, 7.4)
- Instruct patients not to consume alcohol or any products containing alcohol while taking OBREDON because co-ingestion can result in fatal plasma hydrocodone levels. ( 5.8, 7.1)
- OBREDON is not recommended for use in pregnant women. Prolonged use of OBREDON during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If OBREDON is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. ( 5.13, 8.1)
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
OBREDON is a combination of hydrocodone, an opioid agonist; and guaifenesin, an expectorant, indicated for the symptomatic relief of cough and to loosen mucus associated with the common cold in patients 18 years of age and older. ( 1)
Important Limitations of Use: ( 1)
- Not indicated for pediatric patients under 18 years of age.
- Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve OBREDON for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made.
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Oral Solution: Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.( 3)
- Children younger than 6 years of age. ( 4)
- Significant respiratory depression. ( 4)
- Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. ( 4)
- Known or suspected gastrointestinal obstruction, including paralytic ileus. ( 4)
- Hypersensitivity to hydrocodone, guaifenesin, or any of the inactive ingredients in OBREDON. ( 4)
WARNINGS AND PRECAUTIONS
See Boxed WARNINGS
- Life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients: Monitor closely, particularly during initiation of therapy. ( 5.4)
- Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring mental alertness such as driving or operating machinery. ( 5.6)
- Risks of use in patients with head injury, impaired consciousness, increased intracranial pressure, or brain tumors: Avoid use. May increase intracranial pressure and obscure the clinical course of head injuries. ( 5.10)
- Seizures in patients with seizure disorders: Monitor during therapy. ( 5.11)
- Severe hypotension: Monitor during initiation of therapy. Avoid use in patients with circulatory shock. ( 5.12)
- Adrenal insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. ( 5.14)
Common adverse reactions include: Sedation (somnolence, mental clouding, lethargy), impaired mental and physical performance, lightheadedness, dizziness, headache, dry mouth, nausea, vomiting, and constipation ( 6)
To report SUSPECTED ADVERSE REACTIONS, contact Sovereign Pharmaceuticals, LLC at 1-855-461-5102 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue if serotonin syndrome is suspected. ( 7.5)
- Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI. ( 7.6)
- Muscle Relaxants: Avoid concomitant use. ( 7.7)
- Diuretics: Hydrocodone may reduce the efficacy of diuretics. Monitor for reduced effect. ( 7.8)
- Anticholinergic drugs: Concomitant use may cause paralytic ileus. ( 5.9, 7.9)
USE IN SPECIFIC POPULATIONS
See 17 for Medication Guide.
Table of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
5.10 Risks of Use in Patients with Head Injury, Impaired Consciousness, Increased Intracranial Pressure, or Brain Tumors
- Sections or subsections omitted from the full prescribing information are not listed.
- BOXED WARNING (What is this?)
1 INDICATIONS AND USAGE
- Not indicated for pediatric patients under 18 years of age [ see Use in Specific Populations ( 8.4) ].
- 2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
Oral Solution: Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg [see Description ( 11)] .
- Hypersensitivity to hydrocodone, guaifenesin, or any of the inactive ingredients in OBREDON [see Adverse Reactions ( 6)].
5 WARNINGS AND PRECAUTIONS
5.6 Activities Requiring Mental Alertness: Risks of Driving and Operating Machinery
Hydrocodone, one of the active ingredients in OBREDON, may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of OBREDON. Avoid concurrent use of OBREDON with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur [ see Warnings and Precautions ( 5.8) ].
5.10 Risks of Use in Patients with Head Injury, Impaired Consciousness, Increased Intracranial Pressure, or Brain Tumors
Avoid the use of OBREDON in patients with head injury, intracranial lesions, or a pre-existing increase in intracranial pressure. In patients who may be susceptible to the intracranial effects of CO 2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), OBREDON may reduce respiratory drive, and the resultant CO 2 retention can further increase intracranial pressure. Furthermore, opioids produce adverse reactions that may obscure the clinical course of patients with head injuries.
6 ADVERSE REACTIONS
The following serious adverse reactions are described, or described in greater detail, in other sections:
- Addiction, abuse, and misuse [ see Warnings and Precautions ( 5.1), Drug Abuse and Dependence ( 9.3) ]
- Life-threatening respiratory depression [ see Warnings and Precautions ( 5.2, 5.3, 5.4, 5.8), Overdosage ( 10) ]
- Accidental overdose and death due to medication errors [ see Warnings and Precautions ( 5.5) ]
- Decreased mental alertness with impaired mental and/or physical abilities [ see Warnings and Precautions ( 5.6) ]
- Interactions with benzodiazepines and other CNS depressants [ see Warnings and Precautions ( 5.8), Drug Interactions ( 7.1, 7.4) ]
- Paralytic ileus, gastrointestinal adverse reactions [ see Warnings and Precautions ( 5.9) ]
- Increased intracranial pressure [ see Warnings and Precautions ( 5.10) ]
- Obscured clinical course in patients with head injuries [ see Warnings and Precautions ( 5.10) ]
- Seizures [ see Warnings and Precautions ( 5.11) ]
- Severe hypotension [ see Warnings and Precautions ( 5.12) ]
- Neonatal Opioid Withdrawal Syndrome [ see Warnings and Precautions ( 5.13) ]
- Adrenal insufficiency [ see Warnings and Precautions ( 5.14) ]
The following adverse reactions have been identified during clinical studies, in the literature, or during post-approval use of hydrocodone and/or guaifenesin. Because these reactions may be reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions to OBREDON include: Sedation (somnolence, mental clouding, lethargy), impaired mental and physical performance, lightheadedness, dizziness, headache, dry mouth, nausea, vomiting, and constipation.
Other reactions include:
Anaphylaxis: Anaphylaxis has been reported with hydrocodone, one of the ingredients in OBREDON.
Body as a whole: Coma, death, fatigue, falling injuries, lethargy.
Cardiovascular: Peripheral edema, increased blood pressure, decreased blood pressure, tachycardia, chest pain, palpitation, syncope, orthostatic hypotension, prolonged QT interval, hot flush.
Central Nervous System: Facial dyskinesia, insomnia, migraine, increased intracranial pressure, seizure, tremor.
Dermatologic: Flushing, hyperhidrosis, pruritus, rash.
Endocrine/Metabolic: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Cases of androgen deficiency have occurred with chronic use of opioids.
Gastrointestinal: Abdominal pain, bowel obstruction, decreased appetite, diarrhea, difficulty swallowing, GERD, indigestion, pancreatitis, paralytic ileus, biliary tract spasm (spasm of the sphincter of Oddi).
Genitourinary: Urinary tract infection, ureteral spasm, spasm of vesicle sphincters, urinary retention.
Laboratory: Increases in serum amylase.
Musculoskeletal: Arthralgia, backache, muscle spasm.
Ophthalmic: Miosis (constricted pupils), visual disturbances.
Psychiatric: Agitation, anxiety, confusion, fear, dysphoria, depression.
Reproductive: Hypogonadism, infertility.
Respiratory: Bronchitis, cough, dyspnea, nasal congestion, nasopharyngitis, respiratory depression, sinusitis, upper respiratory tract infection.
Other: Drug abuse, drug dependence, opioid withdrawal syndrome.
7 DRUG INTERACTIONS
No specific interaction studies have been conducted with OBREDON.
Concomitant use of alcohol with OBREDON can result in an increase of hydrocodone plasma levels and potentially fatal overdose of hydrocodone. Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products containing alcohol while on OBREDON therapy [ see Warnings and Precautions ( 5.8), Clinical Pharmacology (12.3) ].
7.2 Inhibitors of CYP3A4 and CYP2D6
The concomitant use of OBREDON and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), or protease inhibitors (e.g., ritonavir), can increase the plasma concentration of hydrocodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of OBREDON and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of OBREDON is achieved [ see Warnings and Precautions ( 5.7) ]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the hydrocodone plasma concentration will decrease [ see Clinical Pharmacology ( 12.3) ], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to hydrocodone.
Avoid the use of OBREDON while taking a CYP3A4 or CYP2D6 inhibitor. If concomitant use is necessary, monitor patients for respiratory depression and sedation at frequent intervals.
7.3 CYP3A4 Inducers
The concomitant use of OBREDON and CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, can decrease the plasma concentration of hydrocodone [ see Clinical Pharmacology ( 12.3) ], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to hydrocodone [ see Warnings and Precautions ( 5.7) ]. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the hydrocodone plasma concentration will increase [ see Clinical Pharmacology ( 12.3) ], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.
Avoid the use of OBREDON in patients who are taking CYP3A4 inducers. If concomitant use of a CYP3A4 inducer is necessary, follow the patient for reduced efficacy.
7.4 Benzodiazepines, and Other CNS Depressants
Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Avoid the use of OBREDON in patients who are taking benzodiazepines or other CNS depressants [ see Warnings and Precautions ( 5.8) ], and instruct patients to avoid consumption of alcohol while on OBREDON [ see Drug Interactions ( 7.1), Patient Counseling Information ( 17) ].
7.5 Serotonergic Drugs
The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation. Discontinue OBREDON if serotonin syndrome is suspected.
7.6 Monoamine Oxidase Inhibitors (MAOIs)
Avoid the use of OBREDON in patients who are taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days. The use of MAOIs or tricyclic antidepressants with hydrocodone, one of the active ingredients in OBREDON, may increase the effect of either the antidepressant or hydrocodone. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma).
7.7 Muscle Relaxants
Hydrocodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Avoid the use of OBREDON in patients taking muscle relaxants. If concomitant use is necessary, monitor patients for signs of respiratory depression that may be greater than otherwise expected.interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma).
Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
7.9 Anticholinergic Drugs
The concomitant use of anticholinergic drugs with OBREDON may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [ see Warnings and Precautions ( 5.9) ]. Monitor patients for signs of urinary retention or reduced gastric motility when OBREDON is used concomitantly with anticholinergic drugs.
8 USE IN SPECIFIC POPULATIONS
OBREDON is not recommended for use in pregnant women, including during or immediately prior to labor.
Prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [ see Warnings and Precautions ( 5.13), Clinical Considerations ].
There are no available data with OBREDON use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Published studies with hydrocodone have reported inconsistent findings and have important methodological limitations ( see Data).
Reproductive toxicity studies have not been conducted with OBREDON; however, studies are available with individual active ingredients or related active ingredients ( see Data).
In animal reproduction studies, hydrocodone administered by the subcutaneous route to pregnant hamsters during the period of organogenesis produced a teratogenic effect at a dose approximately 45 times the maximum recommended human dose (MRHD) ( see Data).
Guaifenesin administered by the oral route to pregnant rats during the period of organogenesis was embryolethal at a dose approximately 1 times the MRHD and produced teratogenic effects at a dose approximately 2 times the MRHD ( see Data).
Based on the animal data, advise pregnant women of the potential risk to a fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Fetal/Neonatal Adverse Reactions
Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.
Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [ see Warnings and Precautions ( 5.13) ].
Labor or Delivery
Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Opioids, including OBREDON, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioids during labor for signs of excess sedation and respiratory depression.
HydrocodoneA limited number of pregnancies have been reported in published observational studies and postmarketing reports describing hydrocodone use during pregnancy. However, these data cannot definitely establish or exclude any drug-associated risk during pregnancy. Methodological limitations of these observational studies include small sample size and lack of details regarding dose, duration and timing of exposure.
Animal DataReproductive toxicity studies have not been conducted with OBREDON; however, studies are available with individual active ingredients or related active ingredients.
HydrocodoneIn an embryofetal development study in pregnant hamsters dosed on gestation day 8 during the period of organogenesis, hydrocodone induced cranioschisis, a malformation, at approximately 45 times the MRHD (on a mg/m2 basis with a maternal subcutaneous dose of 102 mg/kg). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In an embryofetal development study in pregnant rats dosed throughout the period of organogenesis, codeine increased resorptions and decreased fetal weights at a dose approximately 65 times the MRHD of hydrocodone (on a mg/m2 basis with a maternal oral dose of codeine at 120 mg/kg/day); however, these effects occurred in the presence of maternal toxicity. In embryofetal development studies with pregnant rabbits and mice dosed throughout the period of organogenesis, codeine produced no adverse developmental effects at doses approximately 30 and 160 times, respectively, the MRHD of hydrocodone (on a mg/m2 basis with maternal oral doses of codeine at 30 mg/kg/day in rabbits and 600 mg/kg/day in mice).
In an embryofetal development study in pregnant rats dosed throughout the period of organogenesis, guaifenesin resulted in fetal death at doses approximately 1 times the MRHD (on a mg/m2 basis with maternal oral doses of 350 mg/kg/day and higher). Guaifenesin also induced hemorrhagic spots and decreases in fetal weight and lengths of full body, skull, fore- and hind-limbs, and tail at doses 1 times the MRHD (on a mg/m2 basis with maternal oral doses of 250 mg/kg/day and higher). Limb and tail defects, increased intercostal space, and improper development of limbs were observed at doses 2 times the MRHD (on a mg/m2 basis with maternal oral doses of 500 mg/kg/day and higher).
Because of the potential for serious adverse reactions, including excess sedation, respiratory depression, and death in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with OBREDON.
There are no data on the presence of OBREDON in human milk, the effects of OBREDON on the breastfed infant, or the effects of OBREDON on milk production; however, data are available with hydrocodone.
Hydrocodone is present in breast milk. Published cases report variable concentrations of hydrocodone and hydromorphone (an active metabolite) in breast milk with administration of immediate-release hydrocodone to nursing mothers in the early post-partum period with relative infant doses of hydrocodone ranging between 1.4 and 3.7%. There are case reports of excessive sedation and respiratory depression in breastfed infants exposed to hydrocodone. No information is available on the effects of hydrocodone on milk production.
No information is available on the levels of guaifenesin in breast milk or on milk production.
Infants exposed to OBREDON through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid is stopped, or when breastfeeding is stopped.
8.3 Females and Males of Reproductive Potential
Chronic use of opioids, such as hydrocodone, a component of OBREDON, may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [ see Adverse Reactions ( 6), Clinical Pharmacology ( 12.2) ].
8.4 Pediatric Use
OBREDON is not indicated for use in patients younger than 18 years of age because the benefits of symptomatic treatment of cough associated with allergies or the common cold do not outweigh the risks for use of hydrocodone in these patients [ see Indications ( 1), Warnings and Precautions ( 5.3) ].
Life-threatening respiratory depression and death have occurred in children who received hydrocodone [ see Warnings and Precautions ( 5.2) ]. Because of the risk of life-threatening respiratory depression and death, OBREDON is contraindicated in children less than 6 years of age [ see Contraindications ( 4) ].
8.5 Geriatric Use
Clinical studies have not been conducted with OBREDON in geriatric populations.
Use caution when considering the use of OBREDON in patients 65 years of age or older. Elderly patients may have increased sensitivity to hydrocodone; greater frequency of decreased hepatic, renal, or cardiac function; or concomitant disease or other drug therapy [ see Warnings and Precautions ( 5.4) ].
Respiratory depression is the chief risk for elderly patients treated with opioids, including OBREDON. Respiratory depression has occurred after large initial doses of opioids were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration [ see Warnings and Precautions ( 5.4, 5.8) ].
Hydrocodone is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, monitor these patients closely for respiratory depression, sedation, and hypotension.
8.6 Renal Impairment
The pharmacokinetics of OBREDON has not been characterized in patients with renal impairment. Patients with renal impairment may have higher plasma concentrations than those with normal function [ see Clinical Pharmacology ( 12.3) ]. OBREDON should be used with caution in patients with severe impairment of renal function, and patients should be monitored closely for respiratory depression, sedation, and hypotension.
8.7 Hepatic Impairment
The pharmacokinetics of OBREDON has not been characterized in patients with hepatic impairment. Patients with severe hepatic impairment may have higher plasma concentrations than those with normal hepatic function [ see Clinical Pharmacology ( 12.3) ]. Therefore, OBREDON should be used with caution in patients with severe impairment of hepatic function, and patients should be monitored closely for respiratory depression, sedation, and hypotension.
9 DRUG ABUSE AND DEPENDENCE
OBREDON contains hydrocodone, a substance with a high potential for abuse similar to other opioids including morphine and codeine. OBREDON can be abused and is subject to misuse, addiction, and criminal diversion [ see Warnings and Precautions ( 5.1) ].
All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic and antitussive products carries the risk of addiction even under appropriate medical use.
Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.
Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.
“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating health care provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.
Abuse and addiction are separate and distinct from physical dependence and tolerance. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.
OBREDON, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.
Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
Abuse of guaifenesin has been linked to the formation of kidney stones composed of the major metabolite β-(2-methoxyphenoxy) lactic acid.
Risks Specific to Abuse of OBREDON
OBREDON is for oral use only. Abuse of OBREDON poses a risk of overdose and death. The risk is increased with concurrent use of OBREDON with alcohol and other central nervous system depressants [ see Warnings and Precautions ( 5.8), Drug Interactions ( 7.1, 7.4) ].
Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
Psychological dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, OBREDON should be prescribed and administered for the shortest duration that is consistent with individual patient treatment goals and patients should be reevaluated prior to refills [ see Dosage and Administration ( 2.3), Warnings and Precautions ( 5.1) ].
Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy.
If OBREDON is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.
Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [ see Use in Specific Populations ( 8.1) ].
Acute overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, partial or complete airway obstruction, atypical snoring, hypotension, circulatory collapse, cardiac arrest, and death.
Hydrocodone may cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [ see Clinical Pharmacology ( 12.2) ].
Overdosage with guaifenesin can cause depression of the central nervous system. While present in polypharmacy overdoses, one case of overdose with only significant levels of guaifenesin has been reported. Symptoms included slurred speech, shallow respirations, reduced heart rate with rhythm sinus bradycardia, followed by asystole.
Treatment of Overdose
Treatment of overdosage is driven by the overall clinical presentation, and consists of discontinuation of OBREDON together with institution of appropriate therapy. Give primary attention to the reestablishment of adequate respiratory exchange through provision of a patent and protected airway and the institution of assisted or controlled ventilation. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. Gastric emptying may be useful in removing unabsorbed drug.
The opioid antagonists, naloxone and nalmefene, are specific antidotes for respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to hydrocodone overdose, administer an opioid antagonist. An antagonist should not be administered in the absence of clinically significant respiratory depression. Because the duration of opioid reversal is expected to be less than the duration of action of hydrocodone in OBREDON, carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information.
Hemodialysis is not routinely used to enhance the elimination of hydrocodone from the body.
OBREDON (hydrocodone bitartrate and guaifenesin) oral solution contains hydrocodone, an opioid agonist; and guaifenesin, an expectorant.
Each 5 mL of OBREDON contains 2.5 mg of hydrocodone bitartrate and 200 mg of guaifenesin for oral administration.
OBREDON also contains the following inactive ingredients: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium.
The chemical name for hydrocodone bitartrate is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5). It is also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It occurs as a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine. It has the following structural formula:
C 18H 21NO 3 • C 4H 6O 6 • 2½H 2O MW= 494.50
The chemical name for guaifenesin is 3-(2-methoxyphenoxy)-1,2- propanediol. It occurs as a white powder and has the following structural formula:
C 10H 14O 4 MW= 198.22
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Hydrocodone is an opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.
Guaifenesin is an expectorant, the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions.
Effects on the Central Nervous System
Hydrocodone produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and to electrical stimulation.
Hydrocodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.
Effects on the Gastrointestinal Tract and Other Smooth Muscle
Hydrocodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.
Effects on the Cardiovascular System
Hydrocodone produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension.
Effects on the Endocrine System
Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [ see Adverse Reactions ( 6) ]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.
Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [ see Adverse Reactions ( 6) ].
Effects on the Immune System
Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.
Concentration–Adverse Reaction Relationships
There is a relationship between increasing hydrocodone plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions.
Following a single 10 mL oral dose of OBREDON, the geometric mean C max and AUC 0-inf for hydrocodone were 12.6 ng/ml and 80.9 ng·hr/ml, respectively, and the geometric mean C max and AUC 0-inf for guaifenesin were 3.7 mcg/ml and 4.2 mcg·hr/ml, respectively. The median time to maximum concentration in plasma for hydrocodone and guaifenesin was about 1.25 hours and 20 minutes, respectively. Food has no significant effect on the extent of absorption of hydrocodone, while the effect of food on guaifenesin systemic exposure is not considered to be clinically meaningful.
Although the extent of protein binding of hydrocodone in human plasma has not been definitively determined, structural similarities to related opioid analgesics suggest that hydrocodone is not extensively protein bound. As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.
Hydrocodone exhibits a complex pattern of metabolism, including N-demethylation, O-demethylation, and 6keto reduction to the corresponding 6-α-and 6-β-hydroxy metabolites. CYP3A4 mediated N-demethylation to norhydrocodone is the primary metabolic pathway of hydrocodone with a lower contribution from CYP2D6 mediated O-demethylation to hydromorphone. Hydromorphone is formed from the O-demethylation of hydrocodone and may contribute to the total analgesic effect of hydrocodone. Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs [see Drug Interactions ( 7)]. Published in vitro studies have shown that N-demethylation of hydrocodone to form norhydrocodone can be attributed to CYP3A4 while O-demethylation of hydrocodone to hydromorphone is predominantly catalyzed by CYP2D6 and to a lesser extent by an unknown low affinity CYP enzyme.
Hydrocodone and its metabolites are eliminated primarily in the kidneys. The mean plasma half-life of hydrocodone is approximately 5 hours.
The mean plasma half-life of guaifenesin is approximately 1 hour.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity, mutagenicity, and fertility studies have not been conducted with OBREDON; however, published information is available for the individual active ingredients or related active ingredients.
Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of codeine. No evidence of tumorigenicity was observed in male and female rats at codeine dietary doses up to 70 and 80 mg/kg/day (approximately equivalent to 40 and 45 times the MRHD of hydrocodone on a mg/m 2 basis, respectively). No evidence of tumorigenicity was observed in male and female mice at codeine dietary doses up to 400 mg/kg/day (approximately equivalent to 110 times the MRHD of hydrocodone on a mg/m 2 basis).
Mutagenicity studies with hydrocodone have not been conducted.
Fertility studies with hydrocodone have not been conducted.
Carcinogenicity, mutagenicity, and fertility studies with guaifenesin have not been conducted
16 HOW SUPPLIED/STORAGE AND HANDLING
OBREDON (hydrocodone bitartrate and guaifenesin) 2.5 mg/200 mg per 5mL is a clear, raspberry flavored oral solution supplied as:
White HDPE bottles of 4 fl oz (118 mL): NDC 58716-433-04
White HDPE bottles of 16 fl oz (473 mL): NDC 58716-433-16
Store solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.
Ensure that patients have an oral dosing dispenser that measures the appropriate volume in milliliters. Counsel patients on how to utilize an oral dosing dispenser and correctly measure the oral suspension as prescribed.
- 17 PATIENT COUNSELING INFORMATION
(hydrocodone bitartrate and guaifenesin) oral solution, C-II
What is the most important information I should know about OBREDON?
OBREDON is not for children under 18 years of age.
OBREDON can cause serious side effects, including:
Addiction, abuse and misuse. Taking OBREDON or other medicines that contain an opioid can cause addiction, abuse and misuse, which can lead to overdose and death. This can happen even if you take OBREDON exactly as prescribed by your healthcare provider. Your risk of addiction, abuse, and misuse is increased if you or a family member has a history of drug or alcohol abuse or addiction, or mental health problems.
- Do not share your OBREDON with other people.
- Keep OBREDON in a safe place away from children.
Life-threatening breathing problems (respiratory depression). OBREDON can cause breathing problems (respiratory depression) that can happen at any time during treatment and can lead to death. Your risk of breathing problems is greatest when you first start taking OBREDON, are taking other medicines that can cause breathing problems, have certain lung problems, are elderly or have certain other health problems.
Children are at higher risk for respiratory depression. Breathing problems can happen even if you take OBREDON exactly as prescribed by your healthcare provider.
Call your healthcare provider or get emergency medical help right away if anyone taking OBREDON has any of the symptoms below:
- increased sleepiness
- difficulty breathing
- shallow breathing
- Keep OBREDON in a safe place away from children. Accidental use of even 1 dose of OBREDON, especially by a child, is a medical emergency and can cause breathing problems (respiratory depression) which can lead to death. If a child accidentally takes OBREDON, get emergency medical help right away.
- Overdose and death due to medicine dosing errors. Overdose and death can happen if you measure the wrong dose of OBREDON. Always use an accurate milliliter (mL) measuring device to measure the correct amount of OBREDON. Do not use a household teaspoon to measure your medicine. You may accidentally take too much. You can ask your pharmacist for the measuring device you should use and how to measure the correct dose.
Breathing problems (respiratory depression) that can lead to death and opioid withdrawalcan happen if you start taking or stop taking other medicines while taking OBREDON, including:
- certain antibiotics
- certain medicines to treat a fungal infection
- certain medicines to treat Human Immunodeficiency Virus (HIV)-1 infection, Acquired Immune Deficiency Syndrome (AIDS), or Hepatitis C
Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider or pharmacist if you are not sure if your medicine is listed above.
Severe drowsiness, breathing problems (respiratory depression), coma and deathcan happen in people who take OBREDON with benzodiazepines or other central nervous system depressants, including alcohol.
- Do not take benzodiazepines or any medicine that can cause drowsiness or sleepiness during treatment with OBREDON.
- Do not drink alcohol or take prescription or over-the-counter medicines that contain alcohol during treatment with OBREDON.
- Opioid withdrawal in a newborn. Use of OBREDON during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated. You should not take OBREDON if you are pregnant. Tell your healthcare provider right away if you are pregnant or think you may be pregnant.
What is OBREDON?
- OBREDON is a prescription medicine used in adults to treat a cough and to loosen mucus that you can have with a common cold. OBREDON contains 2 medicines, hydrocodone and guaifenesin. Hydrocodone is an opioid (narcotic) cough suppressant. Guaifenesin is an expectorant.
- OBREDON is a federal controlled substance (C-II) because it contains hydrocodone that can be abused or lead to dependence. Keep OBREDON in a safe place to prevent misuse and abuse. Selling or giving away OBREDON may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.
Who should not take OBREDON?
OBREDON is not for children under 18 years of age. See “What is the most important information I should know about OBREDON?”
Do not take OBREDON if you:
- have severe breathing problems (respiratory depression) or breathing problems caused by asthma. See “What is the most important information I should know about OBREDON?”
- have a blockage (obstruction) in your bowel such as a paralytic ileus.
- are allergic to hydrocodone, guaifenesin, or any of the ingredients in OBREDON. See the end of this Medication Guide for a complete list of ingredients.
Ask your healthcare provider if you have any questions about this information.
Before you take OBREDON, tell your healthcare provider about all of your medical conditions, including if you:
- have a drug addiction
- have lung or breathing problems
- have a fever and are coughing up mucus
- have had a recent head injury
- have had a brain tumor or other brain problem
- have or have had seizures
- have pain in your stomach-area (abdomen)
- have constipation or other bowel problems
- have bile duct or pancreas problems
- have prostate problems
- have problems with your urinary tract or difficulty urinating
- have kidney or liver problems
- have adrenal gland problems
- have low blood pressure
- plan to have surgery
- are pregnant or plan to become pregnant. OBREDON can harm your unborn baby. See “What is the most important information I should know about OBREDON?”
- are breastfeeding or plan to breastfeed. Hydrocodone passes into your breast milk and can cause serious side effects in your baby including increased sleepiness, breathing problems (respiratory depression), and death. It is not known if guaifenesin passes into your breast milk. You and your healthcare provider should decide if you will take OBREDON or breastfeed. You should not do both.
- plan to have children. OBREDON may affect the ability to have a child in females and males (fertility problems). It is not known if these fertility problems will be reversible, even after you stop taking OBREDON. Talk to your healthcare provider if this is a concern for you.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking OBREDON with certain other medicines can cause side effects or affect how well OBREDON or the other medicines work. Do not start or stop taking other medicines without talking to your healthcare provider.
Especially tell your healthcare provider if you:
- See “What is the most important information I should know about OBREDON?”
- take pain medicines such as opioids (narcotics).
- take cold or allergy medicines that contain antihistamines or cough suppressants.
- drink alcohol.
- take muscle relaxants.
- take certain medicines used to treat mood, anxiety, psychotic or thought disorders, or depression, including monoamine oxidase inhibitors (MAOIs), tricyclics, selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), or antipsychotics.
- take medicines to lower your blood pressure.
- take water pills (diuretics).
- take medicines called “anticholinergics” used to treat certain health problems including asthma, chronic obstructive pulmonary disease (COPD), or stomach problems.
Ask your healthcare provider if you are not sure if you take one of these medicines.
How should I take OBREDON?
- See “What is the most important information I should know about OBREDON?”
- Take OBREDON exactly as your healthcare provider tells you to take it. Do not change your dose without talking to your healthcare provider.
- Take OBREDON by mouth only.
- Take OBREDON using an accurate milliliter (mL) measuring device. If you do not have one, ask your pharmacist to give you a measuring device to help you measure the correct amount of OBREDON. Do not use a household teaspoon to measure your medicine. You may accidently take too much.
- Do not overfill the measuring device.
- Rinse your measuring device with water after each use.
- If you take too much OBREDON, call your healthcare provider or go to the nearest hospital emergency room right away.
- Tell your healthcare provider if your cough does not get better within 5 days of treatment with OBREDON.
What should I avoid while taking OBREDON?
- Avoid driving a car or operating machinery during treatment with OBREDON. OBREDON can cause you to be drowsy, slow your thinking and motor skills, and may affect your vision.
- Do not drink alcohol during treatment with OBREDON. Drinking alcohol can increase your chances of having serious side effects.
- are pregnant. Use of OBREDON during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated. Tell your healthcare provider right away if you are pregnant or think you may be pregnant.
- are breastfeeding. Use of OBREDON while breastfeeding can cause severe breathing problems (respiratory depression) in your breastfed infant that could be life-threatening.
- take a medicine called a monoamine oxidase inhibitor (MAOI). Avoid taking an MAOI within 14 days after you stop taking OBREDON. Avoid starting OBREDON if you stopped taking an MAOI in the last 14 days.
What are the possible side effects of OBREDON?
OBREDON can cause serious side effects, including:
- See “What is the most important information I should know about OBREDON?”
- Bowel problems including severe constipation or stomach pain. See “Who should not take OBREDON?”
- Increased pressure in your head (intracranial). Avoid the use of OBREDON if you have a head injury or have been told that you have changes in the tissue of your brain (brain lesions) or increased pressure in your head.
- Increased risk of seizures in people with seizure disorders. If you have a seizure disorder, OBREDON may increase how often you have a seizure.
- Low blood pressure. A sudden drop in blood pressure can happen in some people during treatment with OBREDON and this may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). Your risk of having this problem may be increased if you take OBREDON with certain other medicines that lower blood pressure. If you have any of these symptoms while taking OBREDON, sit or lie down. Do not change your body position too fast. Get up slowly from sitting or lying down.
- Adrenal gland problems. OBREDON can cause serious and life-threatening adrenal gland problems. Your healthcare provider may do blood tests to check for adrenal gland problems. Call your healthcare provider right away if you have any of these symptoms:
- not wanting to eat (anorexia)
- low blood pressure
The most common side effects of OBREDON include:
- coordination problems
- decrease in mental and physical performance
- lack of energy
- dry mouth
These are not all the possible side effects of OBREDON.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store OBREDON?
- Store OBREDON at room temperature between 20°F to 25°F (68°C to 77°C).
- Store OBREDON in a tightly closed container, in a dry, cool place away from heat or direct sunlight.
- Keep OBREDON and all medicines out of the reach of children.
How should I dispose of OBREDON?
Remove unused OBREDON from the container and mix it with an undesirable, non-toxic substance such as cat litter or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw it away in the household trash. You can also follow your state or local guidelines on how to safely throw away OBREDON.
General information about the safe and effective use of OBREDON.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use OBREDON for a condition for which it was not prescribed. Do not give OBREDON to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about OBREDON that is written for health professionals.
What are the ingredients in OBREDON?
Active ingredients: hydrocodone bitartrate and guaifenesin
Inactive ingredients: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium.
Manufactured by: Sovereign Pharmaceuticals, LLC, Fort Worth, TX 76118
For more information, call 1-855-461-5102.
This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: April 2018
- Addiction, abuse and misuse. Taking OBREDON or other medicines that contain an opioid can cause addiction, abuse and misuse, which can lead to overdose and death. This can happen even if you take OBREDON exactly as prescribed by your healthcare provider. Your risk of addiction, abuse, and misuse is increased if you or a family member has a history of drug or alcohol abuse or addiction, or mental health problems.
Principal Display Panel-16 fl oz. Bottle
16 fl oz. Bottle Label
OBREDON (hydrocodone bitartrate and guaifenesin) oral solution CII
2.5 mg/ 200 mg per 5 mL
Hydrocodone Bitartrate ... 2.5 mg/5 mL
WARNING: May be habit forming.
Guaifenesin ..................... 200 mg/5 mL
16 fl oz. (473 mL)
USUAL DOSAGE: See Package Insert for Complete Dosage Recommendations.
Dispense in a tight, light-resistant container with a child-resistant closure.
WARNING: KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]
Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.
Sovereign Pharmaceuticals, LLC
INGREDIENTS AND APPEARANCE
hydrocodone bitartrate and guaifenesin solution
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58716-433 Route of Administration ORAL DEA Schedule CII Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HYDROCODONE BITARTRATE (UNII: NO70W886KK) (HYDROCODONE - UNII:6YKS4Y3WQ7) HYDROCODONE BITARTRATE 2.5 mg in 5 mL GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN 200 mg in 5 mL Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) GLYCERIN (UNII: PDC6A3C0OX) METHYLPARABEN (UNII: A2I8C7HI9T) POTASSIUM CITRATE (UNII: EE90ONI6FF) POTASSIUM SORBATE (UNII: 1VPU26JZZ4) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PROPYLPARABEN (UNII: Z8IX2SC1OH) WATER (UNII: 059QF0KO0R) SACCHARIN SODIUM (UNII: SB8ZUX40TY) Product Characteristics Color Score Shape Size Flavor RASPBERRY Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58716-433-16 473 mL in 1 BOTTLE; Type 0: Not a Combination Product 12/30/2014 2 NDC:58716-433-04 118 mL in 1 BOTTLE; Type 0: Not a Combination Product 12/30/2014 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA205474 12/30/2014 Labeler - Sovereign Pharmaceuticals, LLC (623168267)